Bachem AG DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

Bachem’s Sustainable TIDES Manufacturing

30 Oct 2024

// PRESS RELEASE

Bachem at Swiss Technology Award 2024

20 Sep 2024

// PRESS RELEASE

Bachem Reports Slight H1 2024 Sales Growth And Confirms Full-Year Outlook

25 Jul 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI India 2024

Booth #1A.I08

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

39 CORPORATE CONTENT #SupplierSpotlight, 2 DATA COMPILATION #PharmaFlow, 121 NEWS #PharmaBuzz

media
39 CORPORATE CONTENT #SupplierSpotlight
2 DATA COMPILATION #PharmaFlow
121 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

47 All APIs, 36 USDMF, 13 CEP/COS, 12 JDMF, 10 KDMF, 46 NDC API, 6 VMF, 28 Listed APIs

47 All APIs
36 USDMF
13 CEP/COS
12 JDMF
10 KDMF
46 NDC API
6 VMF
28 Listed APIs

KEY PRODUCTS

Atosiban, Bivalirudin, Glucagon, Glucagon Hydrochloride, Goserelin Acetate, Lanreotide Acetate, Leuprolide Acetate, Leuprolide Mesylate, Octreotide Acetate, Propofol, Semaglutide, Teriparatide, Teriparatide Acetate, Triptorelin Acetate, Triptorelin Pamoate

Atosiban
Bivalirudin
Glucagon
Glucagon Hydrochloride
Goserelin Acetate
Lanreotide Acetate
Leuprolide Acetate
Leuprolide Mesylate
Octreotide Acetate
Propofol
Semaglutide
Teriparatide
Teriparatide Acetate
Triptorelin Acetate
Triptorelin Pamoate

SERVICES

Analytical, API Manufacturing, API & Drug Product Development

pharmaServices
Analytical
- 1 Analytical Method Development
API Manufacturing
API & Drug Product Development
- 3 API Development

KEY SERVICES

Custom Peptide Synthesis, CMO for Peptide & Oligonucleotide APIs

Custom Peptide Synthesis
CMO for Peptide & Oligonucleotide APIs

INSPECTIONS & REGISTRATIONS

33 FDA, 3 EDQM, 5 GDUFA, 8 Others

inspections
33 FDA
3 EDQM
5 GDUFA
8 Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

About

With more than 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide, providing a wide range of services. Over the years, Bachem has established itself as a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company is headquartered in Switzerland and has offices in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

CPhI India 2024CPhI India 2024

Industry Trade Show

Booth #1A.I08

26-28 November, 2024

India Expo Centre, Greater Noida
Pharma Manufacturing 2...Pharma Manufacturing 2024

Industry Trade Show

Attending

18-19 November, 2024

Boston, MA
13th Austrian Peptide13th Austrian Peptide

Industry Trade Show

Sponsor

05 December, 2024

Vienna, Austria

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Switzerland

Address

Hauptstrasse 144, 4416 Bubendorf

Telephone

+41 585952021

sales.ch@bachem.com

Website

https://www.bachem.com/

https://www.linkedin.com/company/bachem

YouTube

http://www.youtube.com/@BachemGroup

Events

Webinars & Exhibitions

A PHP Error was encountered

Severity: Warning

Message: Undefined variable $tile1

Filename: tabs/exhibitions.php

Line Number: 43

Backtrace:

File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
Line: 43
Function: _error_handler

File: /var/www/html/application/models/CmnPec.php
Line: 1625
Function: view

File: /var/www/html/application/views/include/party/query.php
Line: 575
Function: create

File: /var/www/html/application/views/include/party/indexNew.php
Line: 70
Function: include

File: /var/www/html/application/views/commonNew.php
Line: 445
Function: include

File: /var/www/html/application/controllers/PharmaServices.php
Line: 4643
Function: view

File: /var/www/html/index.php
Line: 224
Function: require_once

Request a meeting

Full Screen View

CPhI India 2024

Booth #1A.I08

envelop Contact Supplier

CPhI India 2024

Booth #1A.I08

CPhI India 2024CPhI India 2024

Industry Trade Show

Booth #1A.I08

26-28 November, 2024

India Expo Centre, Greater Noida
Pharma Manufacturing 2...Pharma Manufacturing 2024

Industry Trade Show

Attending

18-19 November, 2024

Boston, MA
13th Austrian Peptide13th Austrian Peptide

Industry Trade Show

Sponsor

05 December, 2024

Vienna, Austria

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2024

Open PDF

Upload

Corporate Presentation

Open PDF

Upload

Pioneering Sustainable, Large-Scale Tides Manufacturing

Open PDF

Upload

Maintaining a Resilient Tides Supply Chain Under VUCA Conditions

Open PDF

Upload

Scientific Expertise to Spring 2024 Conferences

Open PDF

Upload

Leading the Octreotide Scale-up

Open PDF

Upload

Oligo Therapeutics 2024

Open PDF

Upload

Innovations for Tides 2024

GMP Certificate 2023

Gorerelin Leuprorelin Triptorelin 2024

Open PDF

Upload

Commercial Peptide NCE 2024

Open PDF

Upload

Molecular Hiving™ Technology

Semaglutide 2024

Lanreotide

Back to Stirred Vessels & On to Metric Tons of Oligonucleotides

Open PDF

Upload

Increasing Sustainability in Large Scale Peptide API Purification

Open PDF

Upload

Solid Phase Peptide Synthesis 2023

Open PDF

Upload

Purification- A Bottleneck for Oligonucleotide API Manufacturing

Open PDF

Upload

Manufacturing Complex Peptide APIs

Open PDF

Upload

Interview with Gilles Parmentier

Open PDF

Upload

Leadership Perspectives: Embracing Equity on Women’s Day

Open PDF

Upload

Annual General Meeting 2023

Open PDF

Upload

Innovative Approaches for Large-scale Peptide Production

Open PDF

Upload

Sustainability at Bachem

Open PDF

Upload

In Vitro Diagnostic Peptides 2023

Open PDF

Upload

Innovation for Peptide & Oligonucleotide Manufacturing

Peptide-based In Vitro Diagnostics

Generic APIs-Liraglutide & Other GLP-1 Analogues

Oligonucleotide Facility Virtual Tour

Semaglutide

Leading by Experience in Generic API

Customer Testimonial

Continuous Chromatography of Peptides

Expanding into Oligos - Interview

Thiazine Formation: Elucidation of Thiol-Maleimide Side-Reaction

Oligonucleotides - Innovation that Transforms Lives

Interview with Torsten Wohr

The Perfect Ingredients for a Better World

Sherpany and Futurae

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 2829

FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big

In the intricate world of molecular biology, oligonucleotides stand out as versatile, powerful molecules. Oligonucleotides are essentially short, single strands of DNA or RNA that modulate gene expression. There are various oligonucleotide therapy (ONT) agents (such as antisense, deoxyribozymes, siRNA and CRISPR/Cas) that offer promising therapeutic tools.A variation of gene therapy, oligonucleotide gene therapies (OGTs) are manufactured using synthetic oligonucleotides. These therapies are designed to enter cells. ONTs act like tools that can fine-tune the behavior of certain genetic instructions, and are therefore often designed to treat rare and genetic diseases and cancers. Sometimes, they may be delivered into cells through lipid nanoparticles or adeno-associated viruses (AAV), halting the translation of a specific protein. Oligonucleotides have also revolutionized vaccine development through the creation of nucleic acid vaccines, such as mRNA vaccines.The first oligonucleotide drug, known as fomivirsen, was approved by the US Food and Drug Administration (FDA) back in 1998. It was developed by Ionis Pharmaceuticals (then known as Isis Pharmaceuticals), and was approved to treat a rare eye disease. However, ONT approvals have picked up since 2016. Currently, there are 20 oligonucleotide drugs approved by the FDA and the European Medicines Agency (EMA) and a majority of them treat orphan and rare diseases.In 2023, FDA approved four ONTs — AstraZeneca-Ionis’ Wainua (eplontersen), Novo Nordisk owned Dicerna Pharmaceuticals’ Rivfloza (nedosiran), Biogen-Ionis’ Qalsody (tofersen) and Iveric Bio’s Izervay (avacincaptad pegol).In 2021, the global ONT market size was estimated to be US$ 18.2 billion. It is expected to increase to US$ 51.4 billion by 2029, growing at a compounded annual rate (CAGR) of 13.85 percent. Similarly, the market for oligonucleotides synthesis (or the process of producing oligonucleotides) was estimated at US$ 7.7 billion globally in 2022 and is expected to grow 11.8 percent CAGR to reach US$ 16.4 billion by 2030. Some of the bigger players in oligonucleotides synthesis are Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins, Agilent, Bio-Synthesis, EUROAPI, Eurogentec, STA Pharma, and Bachem.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available)ONTs address neuro disorders; four ONTs bring in US$ 1.24 bn for AlnylamONTs are widely applied to treat neurodegenerative diseases, such as Duchenne muscular dystrophy (DMD). Multiple ONTs have been approved in Europe and the US for DMD, such as Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and Amondys 45 (casimersen) from Sarepta and NS Pharma’s Viltepso (viltolarsen). Last year, Ionis bagged two approvals in the space. FDA approved its Biogen-partnered therapy Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS). The agency also approved AstraZeneca and Ionis’ drug Wainua (eplontersen), rendering it as the first self-administered treatment for a rare nerve damage disease, known as hereditary transthyretin amyloidosis (ATTR-PN). Analysts estimate global peak sales for Wainua to come in at US$ 750 million for ATTR-PN alone. The drug is also being tested for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare heart muscle disorder.Alnylam Pharmaceuticals has also successfully brought four ONTs to market in recent years — Onpattro (patisiran) and Amvuttra (vutrisiran) for rare nerve diseases, and Givlaari (givosiran) and Oxlumo (lumasiran). Givlaari has been approved to treat acute hepatic porphyria (a liver enzyme deficiency) while Oxlumo treats primary hyperoxaluria (a disorder characterized by increased urinary oxalate excretion). The four ONTs brought in US$ 1.24 billion for Alnylam in 2023.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Novartis buys rights to siRNA therapy, GSK bets big on ONT pipeline through dealsAfter Alnylam discovered inclisiran (Leqvio), Novartis acquired global rights to the therapy in a US$ 9.7 billion deal. Leqvio was the first FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction. It brought in US$ 355 million for Novartis in 2023.GSK has increasingly been investing in its ONT pipeline. The British pharma has promised over US$ 5 billion in upfront and milestone payments in multiple deals. In February, GSK exercised its option to license Elsie Biotechnologies’ discovery platform to find and develop novel ONTs. GSK has also entered a discovery collaboration with Wave Life Sciences.Last July, Japanese drugmaker Astellas Pharma completed its approximately US$ 5.9 billion buyout of New Jersey-headquartered Iveric Bio. Iveric focuses on retinal diseases and the deal gives Astellas drug candidates to treat about 160 million people with eye ailments. Subsequently, in August, Iveric’s Izervay (avacincaptad pegol) was approved by the FDA as a new treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).After Novo Nordisk acquired RNAi technology company Dicerna Pharmaceuticals for US$ 3.3 billion in 2021, the latter’s once-monthly RNAi therapy Rivfloza (nedosiran) saw FDA approval last October. Rivfloza was okayed for children nine years and older to treat a rare genetic condition that affects the kidneys, known as primary hyperoxaluria type 1 (PH1).View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Ionis tees up NDAs for rare disease treatments after two late-stage trial winsThe industry is looking for cures to a wide spectrum of diseases like cancer (such as melanoma, pancreatic, liver, glioblastoma, breast and ovarian cancer), cystic fibrosis, Alzheimer’s disease, Parkinson’s disease, hepatitis B, asthma, Rett syndrome, non-alcoholic steatohepatitis, and IgA nephropathy through its research on ONTs.In January, Ionis announced late-stage results wherein its RNA-targeted hereditary angioedema (HAE) candidate, donidalorsen, significantly reduced the rate of HAE attacks in patients treated every four weeks and patients treated every eight weeks. The California-based biotech is readying a new drug application (NDA) to submit to the FDA. HAE is a rare and life-threatening genetic disease that causes unpredictable and frequent severe swelling of the skin, gastrointestinal (GI) tract, upper respiratory system, face and throat. This year, Ionis’ olezarsen was granted fast track designation by the FDA for the rare genetic disease familial chylomicronemia syndrome (FCS). Last September, olezarsen had met its primary endpoint of reducing abnormally high levels of triglycerides in a late-stage trial in patients with the metabolic disorder. Currently, there are no FDA-approved treatments for this condition. If okayed, olezarsen is likely to bring in US $849 million in sales for Ionis by 2032.In March, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in certain adult patients with myelodysplastic syndromes. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024, for Geron’s NDA for imetelstat. It is among the most anticipated drug launches this year.View Our Interactive Dashboard on Oligonucleotide Therapies (Free Excel Available) Our viewDeveloping ONTs is a field fraught with challenges, such as toxicity and drug delivery. There are safety concerns as well as concerns around delivering the therapy. However, technological breakthroughs and collaborations between pharma firms and contract research organizations that focus on drug delivery are continuously working towards addressing these challenges. All in all, we foresee exciting times ahead for ONTs.

Impressions: 3431

NEWS #PharmaBuzz

Bachem’s Sustainable TIDES Manufacturing

30 Oct 2024

// PRESS RELEASE

Bachem at Swiss Technology Award 2024

20 Sep 2024

// PRESS RELEASE

Bachem Reports Slight H1 2024 Sales Growth And Confirms Full-Year Outlook

25 Jul 2024

// PRESS RELEASE

Incident On Construction Site Of Bachem In Bubendorf

28 May 2024

// PRESS RELEASE

Voices On Bachem’S Innovation Culture

30 Apr 2024

// PRESS RELEASE

Bachem Annual General Meeting 2024

24 Apr 2024

// PRESS RELEASE

ALL APIs

Click the button for full data set

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

5-aminolevulinic Acid Hydrochloride

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 9972

Submission : 1992-11-25

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

Ac-137

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 10068

Submission : 1993-02-04

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

Bivalirudin

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 31458

Submission : 2017-03-31

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

Carbidopa

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : Complete

Rev. Date : 2013-07-11

Pay. Date : 2013-06-17

DMF Number : 9231

Submission : 1991-07-11

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

05

Desmopressin Acetate

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : Complete

Rev. Date : 2017-03-31

Pay. Date : 2014-03-27

DMF Number : 9951

Submission : 1992-11-05

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

06

Etomidate

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : Complete

Rev. Date : 2014-10-16

Pay. Date : 2014-10-14

DMF Number : 20234

Submission : 2007-01-29

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

07

Etomidate Process B

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : Complete

Rev. Date : 2023-12-12

Pay. Date : 2023-09-22

DMF Number : 38855

Submission : 2023-09-19

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

08

Exenatide (bulk)

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : Complete

Rev. Date : 2014-03-21

Pay. Date : 2013-09-16

DMF Number : 17227

Submission : 2004-03-05

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

09

Glucagon

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : Complete

Rev. Date : 2015-05-07

Pay. Date : 2015-04-27

DMF Number : 18277

Submission : 2005-04-12

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

10

Glucagon Pharma Grade

Switzerland

CPhI India 2024

Booth #1A.I08

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Bachem AG

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 32703

Submission : 2018-06-08

Status : Active

Type : II

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

VMF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY PRODUCTS

TOP RANKED SUPPLIER FOR:

Services

Discover the service capabilities from this company

Analytical

Discover their expertise for :

Analytical Method Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Manufacturing

Discover their expertise for :

Scale Up

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Clinical Supply

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Small Molecules

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Chiral Synthesis

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GMP Manufacturing

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Custom Synthesis & Manufacturing

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Oligonucleotide / Polynucleotide

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Protein / Peptide

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API & Drug Product Development

Discover their expertise for :

API Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY SERVICES

TOP RANKED SUPPLIER FOR:

Inspections and registrations

Check the inspections & registration from this company

FDA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EDQM

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GDUFA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Others

ABOUT THIS PAGE

Contact Bachem AG and get a quotation

Bachem AG is a supplier offers 43 products (APIs, Excipients or Intermediates).

Find a price of Calcitonin bulk with DMF, CEP, JDMF offered by Bachem AG

Find a price of Carbidopa bulk with DMF, CEP, JDMF offered by Bachem AG

Find a price of Desmopressin Acetate bulk with DMF, CEP, JDMF offered by Bachem AG

Find a price of Goserelin Acetate bulk with DMF, CEP, JDMF offered by Bachem AG

Find a price of Leuprolide Acetate bulk with DMF, CEP, JDMF offered by Bachem AG

Find a price of Octreotide Acetate bulk with DMF, CEP, JDMF offered by Bachem AG

Find a price of Propofol bulk with DMF, CEP, JDMF offered by Bachem AG

Find a price of Etomidate bulk with DMF, CEP offered by Bachem AG

Find a price of Glucagon bulk with DMF, JDMF offered by Bachem AG

Find a price of Gonadorelin Acetate bulk with DMF, CEP offered by Bachem AG

Find a price of Icatibant Acetate bulk with DMF, JDMF offered by Bachem AG

Find a price of Aminolevulinic Acid HCl bulk with DMF offered by Bachem AG

Find a price of Arginine Vasopressin bulk with DMF offered by Bachem AG

Find a price of Bivalirudin bulk with DMF offered by Bachem AG

Find a price of Buserelin Acetate bulk with JDMF offered by Bachem AG

Find a price of Calcitonin bulk with CEP offered by Bachem AG

Find a price of Carbidopa bulk with CEP offered by Bachem AG

Find a price of Corticotropin bulk with DMF offered by Bachem AG

Find a price of Dasiglucagon bulk with DMF offered by Bachem AG

Find a price of Exenatide bulk with DMF offered by Bachem AG

Find a price of Goserelin Acetate bulk with DMF offered by Bachem AG

Find a price of Histrelin Acetate bulk with DMF offered by Bachem AG

Find a price of Lanreotide Acetate bulk with DMF offered by Bachem AG

Find a price of Liraglutide bulk with DMF offered by Bachem AG

Find a price of N-T-Boc-2,5-Dihydropyrrole bulk with DMF offered by Bachem AG

Find a price of Octreotide Acetate bulk with DMF offered by Bachem AG

Find a price of Semaglutide bulk with DMF offered by Bachem AG

Find a price of Sincalide bulk with DMF offered by Bachem AG

Find a price of Somatostatin bulk with CEP offered by Bachem AG

Find a price of Teriparatide bulk with DMF offered by Bachem AG

Find a price of Teriparatide Acetate bulk with JDMF offered by Bachem AG

Find a price of Tetracosactide bulk with DMF offered by Bachem AG

Find a price of Trans-3-Hexenyl Acetate bulk with DMF offered by Bachem AG

Find a price of Triptorelin Pamoate bulk with DMF offered by Bachem AG

Find a price of Vasoactive Intestinal Peptide bulk with DMF offered by Bachem AG

Find a price of Act1 bulk with DMF offered by Bachem AG

Find a price of LUM015 ACETATE bulk with DMF offered by Bachem AG

Find a price of Atosiban bulk offered by Bachem AG

Find a price of Glepaglutide bulk offered by Bachem AG

Find a price of Glucagon Hydrochloride bulk offered by Bachem AG

Find a price of Leuprolide Mesylate bulk offered by Bachem AG

Find a price of Setmelanotide Acetate bulk offered by Bachem AG

Find a price of Triptorelin Acetate bulk offered by Bachem AG

Company profile for Bachem AG

VISIT THE VIRTUAL BOOTH

Review portfolio & marketing content

CONTACT DETAILS

Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

DIGITAL CONTENT

39 CORPORATE CONTENT #SupplierSpotlight

2 DATA COMPILATION #PharmaFlow

121 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

47 All APIs

36 USDMF

13 CEP/COS

12 JDMF

10 KDMF

46 NDC API

6 VMF

28 Listed APIs

KEY PRODUCTS

SERVICES

Analytical

API Manufacturing

API & Drug Product Development

KEY SERVICES

INSPECTIONS & REGISTRATIONS

33 FDA

3 EDQM

5 GDUFA

8 Others

A PHP Error was encountered

01

02

03

04

05

06

07

08

09

10

What are you looking for?